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Accreditation according to an internationally recognized standard is increasingly acknowledged as the single most effective route to com-
prehensive laboratory quality assurance, and many countries are progressively moving towards compulsory accreditation of medical
testing laboratories. The ESHRE PGD Consortium and some regulatory bodies recommend that all PGD laboratories should be accredited
or working actively towards accreditation, according to the internationally recognized standard ISO 15189, ‘Medical laboratories—Particular
requirements for quality and competence’. ISO 15189 requires comprehensive quality assurance. Detailed management and technical
requirements are deﬁned in the two major chapters. The management requirements address quality management including the quality
policy and manual, document control, non-conformities and corrective actions, continual improvement, auditing, management review, con-
tracts, referrals and resolution of complaints. Technical requirements include personnel competence (both technical and medical), equip-
ment, accommodation and environment, and pre-analytical, analytical and post-analytical processes. Emphasis is placed on the particular
requirements of patient care: notably sample identiﬁcation and traceability, test validation and interpretation and reporting of results.
Quality indicators must be developed to monitor contributions to patient care and continual improvement. We discuss the implementation
of ISO 15189 with a speciﬁc emphasis on the PGD laboratory, highlight elements of particular importance or difﬁculty and provide sugges-
tions of effective and efﬁcient ways to obtain accreditation. The focus is on the European environment although the principles are globally
applicable.
Introduction
Preimplantation genetic diagnosis (PGD) is a well-established service
provided in many European countries, and the overall high-quality
standards are attested by the less numbers of reported errors (Goos-
sens et al., 2008; Wilton et al., 2009). Nonetheless, a recent European
survey demonstrated a shortfall in formal quality assurance in PGD
centres. Although some genetic diagnostic laboratories which also
offer PGD were accredited or preparing actively, accreditation was
rare in dedicated PGD laboratories and IVF laboratories providing
PGD (Corvelyn et al., 2008).
The development of a comprehensive quality management system
(QMS) is a time-consuming process, requiring organization, motivation
and investment, which may be particularly daunting and impractical to
small PGD laboratories with limited staff. The QMS can be developed
and used without entering into the formal process of accreditation;
however, the extra investment to achieve accreditation is relatively
minor and the beneﬁts considerable.
Accreditation, according to an internationally recognized standard
such as ISO 15189 (2007) or ISO 17025, represents the formal
recognition of a laboratory’s competence and of their compliance to
the requirements of the standard (Table I) and is recognized as the
single most effective route to comprehensive quality assurance. In
Europe, accreditation is provided by the national accreditation body,
which should be a member of EA (European cooperation for Accred-
itation). The detailed procedure varies slightly between accreditation
bodies, but typically involves one or more external audits by a lead
auditor from the accreditation body and a technical expert, specialized
in the discipline.
The ESHRE PGD Consortium and some regulatory bodies (e.g. the
Human Fertilisation and Embryology Authority—HFEA—in the UK)
recommend that all PGD laboratories should be accredited, according
to the ISO 15189 standard: ‘Medical laboratories—particular
requirements for quality and competence’. In the UK, the HFEA
have made this mandatory (HFEA, 2009). Similarly, the Organisation
for Economic Co-operation and Development (OECD, 2007)
‘Guidelines for quality assurance in molecular genetic testing’ state
that ‘All laboratories reporting molecular genetic testing results for
clinical care purposes should be accredited or hold an equivalent
recognition’.
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ISO 15189 was developed from the more general (and more
complex) standard for general testing laboratories (ISO 17025). The
philosophy is to provide comprehensive cover of medical testing in
the pre-analytical, analytical and post-analytical phases, including
‘arrangements for acquisition, patient preparation, patient identiﬁ-
cation, collection of samples, transportation, storage, processing and
examination of clinical samples, together with subsequent validation,
interpretation, reporting and advice, in addition to the considerations
of safety and ethics in medical laboratory work’.
ISO 15189 contains two main sections: management requirements
and technical requirements (Table II).
Some of the terms and concepts of the standard may be new or
confusing to PGD professionals in the early stages of implementing a
QMS (http://www.eurogentest.org/laboratories/info/public/unit1/
qmanagement/deﬁnitions_v1.xhtml). In this paper, we provide a com-
panion guide to the concepts and implementation of ISO 15189
speciﬁcally in PGD laboratories, with the aim of demystifying and clar-
ifying the standards. The reader is encouraged to acquire a copy of the
standard for consultation with this guide (www.iso.org).
Management requirements
Organization and QMS (ISO 15189: 4.1 and
4.2)
To achieve accreditation, the PGD laboratory needs a quality manual,
quality policy, with speciﬁc measures to ensure document control,
record control, sample control all of which combine to form the
QMS. A QMS is essential for the smooth running and maintenance
of quality in PGD (Vendrell et al., 2009). The QMS is essentially the
sum total of the quality manual, the procedures, controls and
systems in place to ensure quality.
The laboratory must have a designated quality manager responsible
for maintaining the quality manual, implementing the quality policy and
ensuring the application and development of the QMS. This individual
can be full-time, part-time, dedicated to this task alone or sharing the
task with other functions or personnel according to the size, scope
and resources of the laboratory. However, it is essential that while
the QMS is maintained by the quality manager, speciﬁc quality-related
tasks and activities (writing speciﬁc SOPs, audits etc.) are performed
by the appropriate and responsible staff. If staff numbers permit,
ideally the QM should not be someone involved in the day-to-day
clinical operational running of the PGD laboratory. A key aim should
be to achieve a sense of involvement, motivation and ‘ownership’ of
the QMS by operational (i.e. non-management) personnel.
A quality plan is generally revised at least annually, outlining the
speciﬁc targets of the laboratory to improve the quality of its services.
These may include: (i) benchmarking against other PGD laboratories
(e.g. comparison of turnaround times or numbers of errors and inci-
dents reported); (ii) improvements in areas identiﬁed as potential
weaknesses; (iii) improvements in designated, pre-agreed quality indi-
cators (see below); (iv) internal targets for test accuracy and new test
.............................................................................................................................................................................................
Table I Deﬁnitions and comparison of accreditation, certiﬁcation and licensing.
Deﬁnition Involves Delivered by
Accreditation Procedure by which an authoritative
body gives formal recognition that a
body or person is competent to carry
out speciﬁc tasks
Formal recognition by an independent body of
technical competence, as well as compliance
to a QMS
The ‘authoritative body’ is the national accreditation
body of the country concerned. A complete list for
Europe is available at http://www.european-
accreditation.org/content/ea/members.htm
Certiﬁcation Procedure by which a third party gives
written assurance that a product,
process or service conforms to speciﬁc
requirements
Assurance of compliance to a QMS, most
commonly ISO 9001. The scope is variable but
(in contrast to accreditation), there are no
formal requirements for technical competence
A country may have many ‘third parties’ able to
provide certiﬁcation
Licensing The permission, permit from a
governmental agency to operate a
laboratory
Licensing of health-care facilities is distinct from
accreditation and certiﬁcation and does not
necessarily require any evaluation of quality
management or technical competence
Usually mandatory and government-imposed
........................................................................................
Table II Requirements of the ISO 15189 standard.
Management requirements Technical requirements
Organization and quality
management
Personnel
Quality management system
Accommodation and environmental
conditions
Document control Laboratory equipment
Review of contracts Pre-examination procedures
Examination by referral
laboratories
Examination procedures
External services and supplies
Assuring quality of examination
procedures
Advisory services Post-examination procedures
Resolution of complaints Reporting results
Identiﬁcation of control of
non-conformities
Corrective action
Preventative action
Continual improvement
Quality and technical records
Internal audits
Management review
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development and validation; (v) a list of internal and external audits
planned for the year.
An important feature of the QMS is identifying the organizational
relationships between the different entities involved in the service
(in this case, PGD treatment and diagnostic testing). Since PGD is
necessarily multidisciplinary, this aspect of the QMS is particularly
important and a lack of clarity in work ﬂows, reporting lines and
relationships can lead to poor quality of service despite technical
excellence. Moreover, the patient-focused approach, while para-
mount, is not the only relationship of importance. In PGD, other
client–provider relationships exist (e.g. the PGD laboratory has the
IVF clinic as its user). To this end, it is critical to set up clear lines
of communication via email and through regular face-to-face meetings
or teleconferencing, particularly if PGD is carried out in a transport or
satellite setting. All such communications should be traceable.
Document control (ISO 15189: 4.3) and
quality and technical records (ISO 15189:
4.13)
There is a considerable amount of documentation required to fulﬁl the
standards, which can be paper-based, electronic or both. Some may
argue that providing a clinical service does not require extensive docu-
mentation; however, experience shows the value in maintaining robust
services, training, traceability, complaint handling and continuous
improvement. One way of thinking about the difference between lab-
oratories working within a documentation system compared with lab-
oratories without one is the difference between a symphony orchestra
and a jazz band. Both may produce good music but a symphony
orchestra respects a musical score (the standards) and is guided by
a conductor (the documentation system).
The quality manual should be at the core of the PGD laboratory
organization. An effective quality manual describes brieﬂy how the
requirements for the standard are met and acts as an index to pro-
cedures; it should ideally be no longer than 20–30 pages. The
quality manual includes information about the entire organization
and responsibilities of the structure to be accredited—the QMS,
quality policy, personnel, accommodation and environmental con-
ditions, equipment, information systems and reagents, the examination
process (including pre- and post-examination phases) and different
ways of monitoring and assuring the quality of testing. Written docu-
mentation needs to be produced to support every area of work.
There are different types of documents that need to be written
(Table III).
Putting in place the documentation is a considerable task and must
be carefully prepared. We strongly recommend visiting one or two
accredited labs at the beginning of the process of developing the
QMS and documentation system, to beneﬁt from their experience
and, hopefully, to avoid repeating some of their mistakes. Simply,
there are two fundamental requirements:
(1) the documentation must be usable;
(2) it must fulﬁl the requirements of the chosen accreditation
standard.
A good place to start with the documentation is to write the standard
operating procedures for the individual tests that the laboratory
carries out, taking into account the formal requirements of the stan-
dards (ISO 15189, section 5.5.3). Laboratory staff should be involved
from the start and understand these processes clearly, as the tests
represent the backbone of the service. All the other documentation
naturally arises from the examination tests.
The secrets to successful documentation are: ‘write what you do,
do what you write’ and ‘write everything—but just once’. A hierarch-
ical approach to documentation should be used, allowing individual
documents to be revised without the need to also revise management
procedures. One of the keys to successful accreditation is to cross-
reference documents to each other. If one document is updated, it
does not mean that all the other documents need to be updated as
the other documents should refer to the master documents.
By answering a series of questions related to each test, documen-
tation required for the fulﬁlment of the standards can be logically
put into place. For example:
† What is the aim of the test?
† What equipment is required?
† Has the equipment been appropriately installed, calibrated and
maintained?
† How was the test validated?
† What are the limitations of the test?
† What internal quality control is required?
Table III Key types of documents.
Policies They provide statements that the laboratory will follow particular courses of action (e.g. 101.POL); commonly found in the Quality Manual
Procedures They provide instructions on how to enact policies and how to perform the different activities of the lab. These are also known as standard
operating procedures (SOPs). They may be divided into Management Procedures (e.g. 111.MP) and Laboratory Procedures (222.SOP).
It may be useful to provide briefer working instructions or ‘Short Procedures’ (e.g. 333.SP), which can, for example, be conveniently used
at the lab bench. SOPs are required for all laboratory protocols, equipment and processes
Forms These are used to ensure traceability of all relevant actions and results. Management Forms (444.MF) include training logs, induction
records, personnel forms (induction, training and competency logs, health and safety etc.), outcomes of internal audits and minutes of
meetings. Laboratory Forms (555.LF) will include request forms, work sheets and results, reagent batch numbers and results of equipment
checks and maintenance. Forms can be electronic or hand-ﬁlled, but should always be designed to be as simple to use as possible
External
documents
These are relevant to the QMS or the operation of the laboratory, but are not under the lab’s control (e.g. 123.EXT). They may include
laws, regulations, health and safety requirements, guidelines and manuals, as well as documents of other labs and centres: for example,
patient information leaﬂets and consent forms may be external documents under the control of the IVF unit, even if they are written by or
with the PGD team
It is recommended that document/ﬁlenames reﬂect the function of the document; possible abbreviations are suggested.
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† What external quality assessment (EQA) is performed?
† Who is trained to carry out the test and use the required
equipment?
† How are specimens logged in the lab in order to carry out the test?
† How are test results reported, authorized and ﬁled?
† What are the health and safety risks and requirements?
All of these elements should be addressed, but can be documented
according to individual laboratory preference. For example, internal
quality control tends to be test-speciﬁc and so may be better docu-
mented in each test’s SOP; whereas equipment is commonly shared
between many tests, and so would be more efﬁciently described in
a separate SOP for the individual type of equipment (e.g. use of the
ﬂuorescence microscope).
From the outset, careful thought must be given to ‘document
control’ (i.e. the way to ensure that personnel only use approved,
up-to-date documents—ISO 15189, section 4.3). A policy document
describing the measures taken to prepare, approve, distribute,
access, store, change and withdraw documents is essential. In par-
ticular, care must be taken when copies exist to ensure that only
current versions are in circulation, e.g. by permitting only a set
number of printed copies (preferably dated), stored in speciﬁed
locations. When the document is updated, all previous hardcopy
versions of the document are destroyed and replaced with the
new edition. If no digital archive is available, one printed copy—
clearly labelled as ‘expired’—should be kept for as long as required
by your accrediting body (or other regulations). All documents of
the QMS should contain a header which states the name of the
centre, document name, the unique document reference number
(including version number or date of issue) and pagination expressed
as the page number/total number of pages. Controlled documents
need to be clearly identiﬁed, such as printing on coloured paper or
with a speciﬁed coloured header to protect against photocopying.
They should, where relevant, contain information on the people
authorizing and responsible for the document, the document
author, the total number of copies of the document and their
locations, as well as an index, a short introduction or scope and
cross-references to other relevant documents. All this information
can be printed on the document or stored elsewhere in the
control system. The QMS and its documentation can be managed
in any way the laboratory desires; electronically, on paper, or most
commonly as a combination of the two. Dedicated commercial soft-
ware exists to support quality management; further details are avail-
able in a Guidance Report (EuroGentest, 2009).
A ‘document index’ or ‘master sheet’ can be prepared to list the
documents of the QMS and cross-reference them to the sections of
the standard. It may also be convenient to reference external docu-
ments such as laws, policies or recommendations relevant to the
PGD laboratory in this document.
The laboratory must also have a policy that deﬁnes the length of
time that documents and records must be retained (ISO 15189,
section 4.13). Note that the retention of clinical data is often regulated
by national law and/or within hospitals; such regulations must be
respected by the QMS. A useful rule of thumb is to equal or
exceed retention times deﬁned in local or national regulations.
All documents of the QMS must be periodically ‘reviewed’ and
revised when necessary (see ISO 15189 section 4.12). The quality
manager is responsible for maintaining the quality manual and for
ensuring that all personnel are aware of the contents of the manual
and that the policies and procedures are respected. The frequency
is not deﬁned in the standard, with the exception of examination
(test) procedures: ‘5.5.2 Such a review is normally carried out
annually’. It should be noted that ‘review’ does not necessarily imply
‘revision’—if no changes are necessary, it is sufﬁcient to state in a
document review history that the review was performed and the
documents were satisfactory.
The PGD centre needs to establish and implement procedures for
the identiﬁcation, collection, indexing, access, storage, maintenance
and safe disposal of quality and technical records. This information
can be included in the policies on document control. The PGD
centre needs to deﬁne the length of time such data is stored. This
will relate to request forms, reports, instrument printouts, lab work
books, complaints, staff training etc.
Review of contracts (ISO 15189: 4.4)
It is essential that there is a contract or third-party agreement between
the PGD centre and the IVF unit(s), even if they are part of the same
organization. This document must clearly state what is expected from
the PGD team, the scope of services offered and methods to be used
and conﬁrm that the PGD centre is capable of meeting the require-
ments with appropriate resources and staff and that there will be
regular reviews and records of relevant discussions. This document
may incorporate, or be complemented by, more detailed Terms
and Conditions (outlining such issues as expected test volumes,
costs, turnaround times, sample rejection criteria, laboratory
working hours etc.).
Examination by referral laboratories (ISO
15189: 4.5)
This concerns tests and services which are referred to external labora-
tories. This may include genetics laboratories that perform familial
mutation testing or karyotyping as preparation for PGD, when a test
is not available in-house or when a second opinion may be required.
A procedure must be developed for the choice of competent part-
ners, and the laboratory must follow up and keep records of all
referrals.
External services and supplies (ISO 15189:
4.6)
There must be a procedure for the selection and use of external ser-
vices, equipment and consumables (see section B3). It is important to
identify ‘critical reagents, supplies and services that affect the quality of
examinations’; these and their suppliers must be followed more
closely and must also be veriﬁed before clinical use (either experimen-
tally or by using the manufacturer’s documentation). For example,
PCR tubes or micropipette tips may be considered critical, whereas
agarose for analytical gels is not.
One requirement of this section commonly causes concern in lab-
oratories and so is critical to implement efﬁciently: the requirement to
trace lot numbers (section 4.6.3). The optimal solution to this require-
ment depends on the size and organization of the laboratory and com-
munication with or a visit to an accredited lab may be helpful to see
solutions in action.
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Advisory services (ISO 15189: 4.7)
For PGD laboratories, this concerns principally the interactions with
the IVF clinicians, who may need advice and guidance in preparing
for testing or in future planning. There is an overlap with the contri-
bution to patient care mentioned in ISO 15189 section 4.12.4.
Resolution of complaints (ISO 15189: 4.8)
Peter Drucker (1909–2005), one of the pioneers of modern manage-
ment, stated that ‘Quality in a service or product is not what you put
into it; it is what the customer gets out of it’. ISO 15189 reﬂects this by
the requirement for the laboratory to develop a system to record and
resolve feedback from clinicians, patients or other parties. Although it
is a formal requirement to record and resolve complaints, it is rec-
ommended to extend the system to include positive feedback and
requests for information. Such information provides a valuable
quality indicator and can contribute to continual improvement. If,
for example, there are many identical telephone requests (‘what is
your fax number?’), it is clear that the lab is not providing the infor-
mation appropriately to its users.
The simpler the registration system, the higher the chance is of
regular usage by personnel and, in turn, of obtaining a comprehensive
overview. Figure 1 shows an example form, in use for many years in an
accredited molecular genetics laboratory; copies are kept next to all
telephones, and the form is widely used and easily analysed.
Centres should regularly review user satisfaction with their services
by actively seeking feedback, although this is not a formal requirement
of ISO 15189 (section 4.8). In the case of PGD, this concerns princi-
pally the IVF unit(s) with whom they work, but—according to the
organization—may also include other medical professionals and
patients.
For local IVF centres, this can be achieved through regular meetings;
an agenda should be circulated to all staff, both teams should have free
access to add important issues to the agenda and minutes must be
taken and followed up at the start of each meeting. Meetings may
not be practical for other users, notably in the case of transport
PGD; in such cases, a questionnaire-based user-satisfaction survey
can be used. User satisfaction is an important element of the manage-
ment review (see ISO 15189 section 4.15).
Non-conformities, corrective actions and
preventive actions (ISO 15189: 4.9–4.11)
These elements can be confusing to newcomers to quality manage-
ment; however, when successfully implemented, they provide some
of the major beneﬁts to the laboratory.
‘Non-conformity’ (also known as non-compliance) exists when any
aspect of the laboratory’s activity is identiﬁed as not conforming with
its own procedures or with the agreed requirements of the requesting
clinician or the QMS. The laboratory is required to react to the non-
conformity. This typically initially involves ‘corrective action’ to elimin-
ate or reduce the effect of the non-conformity. In the case of ‘critical’
non-conformities, which may have an impact on patient care, the cor-
rective actions may need to be performed urgently; it may also be
necessary to suspend the activity in question, to avoid any risk of
recurrence.
Following the immediate corrective actions, the root cause should
be identiﬁed. If there is a risk of recurrence (which is almost always
the case), appropriate ‘corrective actions/preventive actions
(CAPA)’ should be designed and implemented. A follow-up audit
should be planned to ensure that the CAPA was effective (that is,
had the desired effect) and efﬁcient (effective without an excessive
increase in workload).
As with suggestions and complaints (ISO 15189 section 4.8),
the initial registration of non-conformities should be simple and acces-
sible to all personnel; the results should be rapidly transmitted to and
analysed by appropriate staff. A simple procedure should also exist to
encourage the proposal of preventive actions before the detection of
non-conformities, for example, by way of a ‘suggestions box’.
An important route to and indicator of the successful implemen-
tation of a QMS is the clear distinction between ‘non-conformity’
and ‘blame’. The identiﬁcation of a non-conformity is almost always
a sign of a fault in the system, rather than a fault or error by an indi-
vidual. Personnel should be encouraged to identify and react to non-
conformities, but discouraged from denouncing individual people.
A ‘blame culture’ discourages reactions to problems and severely
impairs the possibility of quality improvement.
Continual improvement (ISO 15189: 4.12)
Quality improvement is both a formal requirement and a natural
outcome of ISO 15189, based on regular audit and review of pro-
cedures, training for personnel and users, CAPA, and any other appro-
priate mechanism. A successful QMS is dynamic and will evolve to
better meet the needs of users (improvement of quality, efﬁcacy)
and to reduce the workload on personnel (efﬁciency). The system
must therefore be regularly or continuously evaluated to identify
areas for improvement. The quality improvement cycle was famously
described by Deming (Fig. 2).
ISO 15189 section 4.12.4 requires that ‘Laboratory management
shall implement quality indicators for systematically monitoring and
evaluating the laboratory’s contribution to patient care’. Quality indi-
cators are a common source of bemusement to newcomers but in fact
represent a valuable tool not only in measuring improvement in lab
performance, but also in demonstrating these improvements, to
staff, users and management alike.
As usual, the standard requires the implementation of quality indi-
cators but does not impose a speciﬁc solution or a list: this must be
produced by each laboratory according to its activities. Quality indi-
cators should be developed to cover as much of the laboratory’s
activity as possible, including both technical and management
aspects. Quality indicators have to be SMART: speciﬁc, measurable,
achievable, relevant, time-bound. Therefore, for each quality indicator,
it needs to be documented how and how often it is going to be
measured, what are the limits and what happens if the limits are not
met. For example, the PCR contamination rate is a quality indictor
that could be measured every 10 cases with a limit of less than 5%.
If this limit is exceeded, the PCR team would need to determine
why this limit is being exceeded.
Quality indicators will typically be analysed for and presented at the
Annual Management Review (see ISO 15189 section 4.15). Labs are
recommended to develop systems for collecting data on an ongoing
basis, to ensure a constant overview and to simplify analysis and
reporting. Table IV provides examples of quality indicators which
can be useful or can be easily adapted to different laboratories.
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Figure 1 Example of a simple form for noting and following up complaints and requests for information. Note that Type 3 complaints (related to a
laboratory error of some sort) require the generation of a non-conformity and corrective actions. NC: non-conformity; CA: corrective action; TAT:
turn around times.
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Internal audits (ISO 15189: 4.14)
An audit is a systematic, independent and documented process of
obtaining evidence and evaluating it objectively to determine the
extent to which criteria are fulﬁlled. Internal audits review and evaluate
laboratory activity and the QMS with respect to set criteria, to evalu-
ate the extent to which services meet the needs and requirements of
users and comply with the accreditation standard. ISO 15189 requires
that particular emphasis be given to areas critically important to
patient care. Where indicated, CAPA changes are implemented and
further monitoring is used to conﬁrm improvement.
Internal audits are typically conducted by the lab’s own staff,
although it is theoretically possible to use an external consultant. As
personnel should not audit their own activities, it can be beneﬁcial
to implement ‘crossed audits’ between different sections of the
laboratory or centre.
For PGD scientists, internal auditing can be one of the most difﬁcult
elements of a QMS to implement successfully; it is recommended that
at least one member of staff is trained in auditing, either by following
an experienced auditor or in a formal training course (see ISO 15189
section 5.1).
Audits can be performed in different ways. ‘Horizontal audits’
examine a single step in a procedure, across a number of instances,
e.g. CFTR gene mutation testing for 1 year. ‘Vertical audits’ inspect the
sequential steps of a particular procedure, e.g. a PGD for cystic ﬁbrosis,
from receipt of the family samples to completion. ‘Examination (or
witness) audits’ involve observing and questioning an operator perform-
ing a particular procedure, to determine understanding of and compli-
ance with the documented protocol (e.g. does the operator perform
all critical steps of the procedure in the sequence deﬁned by the
SOP). Audits also involve a ‘documentary’ aspect, checking the policies
and procedures in the QMS. In reality, most internal audits are ‘mixed’,
containing elements of all these techniques in varying proportions.
Whichever technique is employed, the main elements of the QMS
should be audited every year (ISO 15189 section 4.14.2). To achieve
this effectively, the organization must prepare an ‘annual audit plan’ and
implement a policy and procedureson the internal audit process including
planning and performing audits, reporting audit results, corrective and
preventive action and communication of the audit ﬁndings. The precise
organization and timing of audits is left to the choice of the laboratory.
Performing more frequent audits makes each one quicker and simpler
to perform and follow-up, but also means that there are few months
without an audit activity. Table V shows an example of an annual plan;
many different schedules are possible and each labmust ﬁnd its preferred
solution. Most probably perform 3–7 internal audits per year.
All audits should result in a written report, describing how the evalu-
ated elements of the QMS comply with requirements. A template audit
report form should be used. An audit may often necessitate a re-audit so
there should be a clear re-audit cycle. Oneway to do this is to construct a
re-audit calendar which clearly lists all the re-audits necessary. A re-audit
form should be used to report the re-audit. The reports of all audits
should be reported to the laboratory QM meeting.
Audits often generate corrective or preventive actions which in turn
should be described and implemented. As stated in ISO 15189 sections
4.9–4.11 earlier, CAPA should be followed up to evaluate their effective-
ness and efﬁciency. The time interval to the follow-up should be intelli-
gently chosen according to the situation: a corrective action that is
potentially critical to patient care might need following-up rapidly
(even, conceivably, same day), whereas others can be evaluated at the
following year’s audit.
Management review (ISO 15189: 4.15)
The PGD centre management must review the QMS and all the
medical activity. The review has two major aims:
Figure 2 The ‘Deming’ or ‘PDCA’ cycle is a rolling circle of four
compartments; Plan, Do, Check and Act. Plan, establish objectives
and identify the necessary processes to achieve them; Do, implement
the new processes; Check, measure and compare the results against
the expected outcome; Act, analyse any differences and the level of
performance, if necessary, repeat the PDCA cycle.
........................................................................................
Table IV Examples of quality indicators for PGD and
molecular genetics laboratories.
Technical Management
Number of new tests deployed Complaints (and
compliments)Number of patients/PGD cases tested
Complaint response timesNumber of tests performed/outsourced
Customer satisfaction
survey
Positive result rate
Meetings with IVF unit
TAT/turnaround time (including from
patient DNA reception to preparatory
work-up being completed) Analytical non-conformities
External quality assessment results Outcomes of external
auditsInternal quality control (IQC) results/
score (intermediate precision) Documents revised and
createdTest failures
Outcomes of internal auditsNumber/level of PCR contaminations
Corrective action
completion
Diagnosis per embryo/single cell
Unplanned absence
(including sick leave)
Conﬁrmation of results in untransferred
embryos
Maintenance of stafﬁng
levels
Misdiagnosis per untransferred embryo/
pregnancy
Maintenance of
accreditation
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† to ensure the suitability and effectiveness of the services and QMS
for patient care;
† to identify and introduce any necessary changes or improvements.
The review is typically performed as an annual management review
but a shorter interval should be adopted when the QMS is being
established.
The required content of the review is detailed in the standard
(Table VI). In the context of PGD, it should also include a summary
of the PGD cases in the previous period [if the PGD is being per-
formed with multiple users (IVF centres), the total results for all IVF
units should be included] and an update on stafﬁng levels. The
reports from the managerial and supervisory personnel could
include a summary of the activities of the centre, publications, meet-
ings attended, training and education. Reports following a detailed
analysis of relevant quality indicators are particularly valuable;
examples of suitable indicators are presented in Table V.
Action plans must be developed for decisions and other tangible
outcomes of the management review. The results should be commu-
nicated appropriately to personnel.
Technical requirements
Personnel (ISO 15189: 5.1)
The requirements of ISO 15189 with respect to personnel are based
on the principle that there should be sufﬁcient competent personnel
to meet the needs of the laboratory and that documentary evidence
of this be readily available. The central concept, ‘competence’, can
be generally understood as the product of basic academic, postgradu-
ate and continuing education, as well as training and experience.
The PGD laboratory shall be directed ‘by a person or persons
having executive responsibility and the competence to assume respon-
sibility for the services provided’ (ISO 15189 section 5.1.3). The
precise requirements for such competence are not detailed but are
commonly speciﬁed elsewhere by the national professional group. In
the UK, for example, this is recognized as being a member of the
Royal College of Pathologists or equivalent, and only this person can
sign-off reports. In addition to the responsibilities of running the
PGD laboratory, the director’s job description and competence
must include the technical and managerial elements speciﬁed by the
standard (ISO 15189 section 5.1.4).
Note that the phrase ‘by a person or persons’ implies that respon-
sibilities can be distributed between different individuals. It is simply
necessary that each essential task is the responsibility of an identiﬁed
individual and that appropriate provisions for his/her replacement are
made in the case of absence.
The laboratory must also appoint a ‘quality manager’ (however
named) with delegated responsibility and authority to oversee compli-
ance with the requirements of the QMS.
Although it is essential in PGD that the procedures be carried out by
suitably qualiﬁed personnel (Geraedts et al., 2001; Vendrell et al., 2009),
currently no recognized training programmes exist. In some cases, this
may lead to inappropriate situations where, for example, the medical
director may wish to perform the biopsy and the clinical embryologist
the FISH or PCR. All personnel must be fully trained to perform the
tasks which theywill undertake. Biopsy should be performed by a clinical
embryologist who is performing embryology on a regular basis; in most
countries, some form of certiﬁcation exists (e.g. ESHRE have developed
a system for certiﬁcation of clinical embryologists; www.eshre.org). FISH
should be performed by a suitably qualiﬁed cytogeneticist and PCR by a
molecular geneticist. The most important issue is that whoever per-
forms the testing must have appropriate training in single-cell diagnosis
(Harton et al., in preparation).
Personnel (laboratory, management and administrative staff) must
have deﬁned initial and continuous ‘training programmes’,
Table VI Items to be included in the management
review.
(a) Follow-up of previous management reviews
(b) Status of corrective actions taken and required preventive action
(c) Reports from managerial and supervisory personnel
(d) The outcome of recent internal audits
(e) Assessment by external bodies
(f) The outcome of external quality assessment and other forms of
interlaboratory comparison
(g) Any changes in the volume and type of work undertaken
(h) Feedback, including complaints and other relevant factors, from
clinicians, patients and other parties
(i) Quality indicators for monitoring the laboratory’s contribution to
patient care
( j) Non-conformities
(k) Monitoring of turnaround time
(l) Results of continuous improvement processes
(m) Evaluation of suppliers
And additionally for PGD (not listed in the standards)
Summary of PGD cases for all the IVF centres (n)
According to ISO 15189, section 4.15.2: ‘Management review shall take account of, but
not be limited to:’.
Table V Example annual internal audit plan, for ISO
15189.
March Organization and management, QMS, management review
April Personnel, training and continuous education, competence
May Witness audit of one analytical procedure (including
examination procedures, assuring quality of examination
procedures, health and safety, accommodation and
environment)
June Equipment and instruments, reagents, external services and
supplies
September Non-conformities, internal audit, corrective/preventive
actions
October Vertical audit: one sample from pre- to post-analytical
(including examination procedures, assuring quality of
examination procedures, health and safety, accommodation
and environment)
November Reporting of results, quality and technical records, advisory
services, referral laboratories, document control
January Annual Management Review
The annual management review is included in this plan for convenience.
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encompassing all areas of work including as appropriate the use of
equipment, SOPs, data protection, training in the IVF unit and
health and safety.
Personnel must receive ‘training in quality assurance’ and quality man-
agement (ISO 15189 section 5.1.6). This should be adapted appropri-
ately to their tasks; secretaries, cleaning staff, technicians and scientists
will have very different needs. As mentioned above, personnel perform-
ing internal audits must receive speciﬁc training. Such training can be per-
formed in-house by staff with experience in quality management, by
visits to other laboratories, or in formal quality management training
programmes such as the EuroGentest (2009) Workshops on
Accreditation.
In all cases, it is necessary to document that training has been per-
formed and that it was effective: i.e. from a speciﬁed date, the person
is ‘competent’ to perform the task. In some situations, formal compe-
tency tests will be required, for example, for an apparatus or a test
procedure; in other cases, competence can be tested by the trainer
based on common sense and observation. It may be appropriate for
the formal authorization of competence (required by ISO 15189
section 5.1.7) to be signed by the trainee (‘I believe I am competent
to do this’), by the trainer (‘this person is competent’) and by the
director who is responsible for the accuracy of the ﬁnal result.
Training should be given by an appropriate person and records kept
in the staff’s logbook. All staff need to keep a log of their continuing
professional development (CPD) to ensure continual updating of
their competency. The laboratory should have a policy for maintaining
competence, for example, for tests that are performed very rarely or
in the case of prolonged absence of speciﬁc personnel.
Although not a formal requirement of ISO 15189, all staff should have
an annual appraisal interview, typically with their line manager. Apprai-
sals should take into account what has been achieved since the last
appraisal, if there were any obstacles to obtaining these, a summary
of training taken and what training needs to be conducted in the follow-
ing year. This interview thus provides a valuable tool for evaluating the
effectiveness of training and for identifying necessary or useful future
training, as required by the standard. Staff should be given the form
to complete in advance of the appraisal date and this should be
returned to the interviewee to access. Formal record should be kept.
Policies and procedures for ‘personnel management’ should describe
how the personnel system is operated, including the professional direc-
tion (who directs the centre), an outline of the stafﬁng of the PGD
centre (who is employed, in which positions), replacements, recruit-
ment, personnel records (what they are and where they are stored),
staff orientation and induction, job descriptions and contracts, staff
records, the annual appraisal process, staff training and education and
continued professional development. A conﬁdential ﬁle should be
kept for all staff with copies kept by the laboratory manager and the
staff member. This should include job title, job descriptions, contracts,
terms and conditions, accountability and responsibility, induction, edu-
cation and CPD, absence records, accident records, occupational
health, disciplinary action, staff meetings and annual reviews.
Accommodation and environmental
conditions (ISO 15189: 5.2)
As is the case with personnel, the accommodation and environment of
the PGD laboratory must be ‘adequate’ for the tasks and the
workload, without compromising quality, safety or patient care. The
standard does not deﬁne precisely the requirements, which are typi-
cally considered as a matter of professional judgement. In this
respect, the accreditation body may make use of published guidelines
(e.g. Thornhill et al., 2005).
The procedures for ‘accommodation and environment’ must
include details of the facilities for staff, patients, storage, health and
safety. This should include a plan of the PGD centre and a description
of the facilities, an outline of the facilities speciﬁcally for staff (this
should include adequate toilet and rest areas and somewhere to eat
and drink) and patients (patients may only be seen at the IVF centre
and may not attend the PGD centre, but if they do, the facilities
need to be under quality management). Facilities for storage must
include details of how samples, consumables, hazardous substances,
drugs, reagents and waste materials are stored. The laboratories,
ofﬁces and storage areas must be well organized and in a good state
of repair. As is usual, the standard does not include PGD-speciﬁc
requirements; these should be speciﬁed with a mix of professional
judgement and common sense.
PCR facilities provide a good example of how to interpret the
standard within a speciﬁc domain. Separate pre- and post-PCR
facilities are widely regarded as essential in diagnostic facilities, and
indeed their absence would almost certainly preclude accreditation
of a PGD lab; yet the standard contains no mention at all of pre- or
post-PCR facilities. In contrast, section 5.2.6 states that ‘There
shall be effective separation between adjacent laboratory sections
in which there are incompatible activities. Measures shall be
taken to prevent cross-contamination’; a technical assessor would
certainly interpret this as a formal requirement to separate the two
activities.
The formal requirements of the standard concerning health and
safety are not very detailed, requiring principally training to avoid
adverse incidents, appropriate environment and safe usage of equip-
ment. While it is probable that the majority of health and safety
policy and procedures will be deﬁned by applicable legislation, which
takes precedence over accreditation requirements, the laboratory
should consider deﬁning and documenting its health and safety pro-
cedures at the same time as preparing for accreditation. Because of
the impossibility of controlling egg collection dates, which is dependent
on the patients’ response to stimulation, many PGD centres will
perform diagnosis seven days a week. The health and safety pro-
cedures should address ‘out-of-hours’ practices, including lines of
communication, authorization for working alone and/or out-of-hours
and professional responsibility, in accordance with applicable legislation.
Procedures should document ‘good laboratory practice’, e.g. the
use of personnel protective equipment, safe working in the laboratory
including protective equipment (such as laboratory coats, wearing
gloves, safety glasses), safe use of equipment, chemicals and reagents
and general laboratory housekeeping such as cleaning and end-of-day
and end-of-week procedures. It can be useful to have existing and new
staff sign safety procedures, for traceability.
This section also addresses control of access. The ‘rules for access’
by personnel, visitors and patients should be clearly deﬁned and a log
of visits should be kept. It is common practice to require visitors to
sign in and out in a log book which contains a brief summary of the
conditions for visitors and a pledge to respect professional
conﬁdentiality.
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Laboratory equipment (ISO 15189: 5.3)
Note that the term ‘equipment’ speciﬁcally includes not only appar-
atus and instruments, but also all consumables, reagents, reference
materials and also computer software used in examination
procedures.
The simple requirement is once again that the laboratory is
equipped with all items required for provision of its services. The
text of 5.3.2 is central: ‘Equipment shall be shown (upon installation
and in routine use) to be capable of achieving the performance
required and shall comply with speciﬁcations relevant to the examin-
ations concerned’. On due consideration, it is evident that meeting
these requirements requires intelligent planning, organization and
effort.
† First, the ‘performance speciﬁcations’ must be deﬁned, for each
examination and for all associated equipment.
† Equipment must be selected that will comply with these
speciﬁcations.
† Before use in testing, equipment must be ‘shown to be compliant’
by the laboratory; this is clearly related to validation and veriﬁca-
tion, also addressed in ISO 15189 section 5.5.
† The laboratory must also be able to show that equipment meets
requirements on a continuous basis: this implies appropriate use
of internal quality control, calibration and maintenance.
† In the case of ‘repair’, it must again be shown that the equipment is
compliant.
† The laboratory must have appropriate procedures in the case of
‘failure’ of critical equipment (e.g. back-up equipment, service con-
tracts, timely repair or replacement or outsourcing of examin-
ations). Note that, in the PGD laboratory, failure of critical
equipment is arguably more signiﬁcant than in many routine
testing laboratories as a result of the rapid turnaround times and
inability to retest many single-cell samples.
New equipment should be purchased according to standardized,
documented procedures; the performance criteria for the intended
application should be documented. All equipment must be uniquely
identiﬁed, and the laboratory must maintain a complete inventory of
equipment. It is useful for laboratory management to designate a refer-
ence person for each item (or class) of equipment, including infor-
mation technology, to oversee the instrument and as a contact in
the case of malfunctioning or other related issues.
Complete equipment records must be maintained. Instructions for
use must be readily available in a language readily understood by the
relevant personnel. One convenient solution uses a folder for each
instrument, stored next to the instrument, documenting all the
elements listed in ISO 15189 section 5.3.4, as well as a form identifying
trained authorized users (this information should also be stored in
their training logs) and a history of relevant calibrations and controls,
failures, performance checks and repairs.
Monitoring of equipment can be performed manually or automati-
cally and intermittently or continuously. The required monitoring
must be deﬁned for each individual item of equipment, but should
be proportional. A liquid nitrogen container or an incubator for
embryo culture requires continuous monitoring and an
out-of-temperature alarm, but this may be excessive (and excessively
costly) for a refrigerator for storage of routine reagents: it may be
sufﬁcient simply to record the temperature manually once per
week, e.g. before opening on Monday morning. Acceptable tempera-
ture ranges must be deﬁned for all incubators and ‘cold-chain’ equip-
ment. The acceptable duration of out-of-range events should also be
considered, to avoid excessive alarms every time a freezer is opened;
it is common practice to keep temperature probes in a tube of 50%
glycerol if brief changes in temperature are not signiﬁcant. Zonal
changes within equipment should also be considered (top–bottom
and front–back).
For some critical instruments, it can be useful to have a brief SOP
with emergency procedures on the instrument. For example, an incu-
bator could indicate a procedure for and out-of-temperature failure,
such as
‘If above 38.58C:
(1) move cultures to back-up incubator no. 123;
(2) contact maintenance on telephone 456789;
(3) contact scientist Dr X;
(4) document on form A1’
Computer software and systems must be addressed in the same way as
instruments: their compliance to requirements must be shown, instruc-
tions must be available, and training and authorization is necessary
before use. Patient conﬁdentiality must be respected, on primary
systems and on back-ups. Competence records must indicate which
staff is authorized to use information systems and/or to enter data.
The documented instructions on usage, validation and maintenance
should also consider the issue of data back-up and software upgrades.
If software is upgraded, it will probably be necessary to revaluate its com-
pliance in some way. When critical programmes are installed on per-
sonal computers, it is often appropriate to disable automatic updates
of the operating system, which can potentially lead to incompatibilities.
In general, it is not necessary to validate and document equipment that
is non-technical and non-critical, e.g. a photocopier or aword-processor.
Common sense and professional judgement must be used to determine
whether performance is critical for the examination procedures: a
camera that is simply used to photograph a mini-gel may not need con-
sideration, but one that is used to capture FISH images (the interpretation
of which directly affect patient care) will need validation, control and
routine preventative maintenance and periodic servicing.
The issue of the cohabitation of diagnostic testing and research
activities, with shared use of space, instruments and reagents, must
be considered. There is no formal barrier in the standard to this,
but it adds two constraints. Firstly, it is necessary to be entirely
clear what activity is included within the accreditation scope; typically,
only diagnostic testing would be included although research and devel-
opment, leading to new diagnostic tests, may also be included. Sec-
ondly, it is appropriate that all personnel should work according to
the rules of the accredited activity. Initially this can lead to resistance
from research personnel; but the beneﬁts of working under more con-
trolled and reliable conditions often provide a convincing argument. It
is important to note that the validation of tests, which can be at the
routine/research interface, must be performed on production equip-
ment, and therefore within the accredited environment.
Documentation should address all aspects of equipment acquisition
and use. Purchase of equipment should follow standard protocols com-
prising product criteria, manufacturing criteria, and risk and
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safety evaluation. All received goods should be controlled, identiﬁed,
registered and released according to SOPs. Home-made reagents
shouldmeet described quality criteria and records be available for audit-
ing. Composition, concentration and date of fabrication and/or expiry
date must be clearly identiﬁed; as expiry dates must be respected, it is
recommended to indicate them on reagents wherever possible. Stock
should be managed; in particular, supplies of critical reagents must be
assured. Hazardous reagents should be registered, labelled, stored,
managed and used appropriately, waste disposal (chemical, infectious,
hazardous) must be described, although the details typically depend
on local legislation rather than the standard. All consumables used for
clinical work must be logged in and a record taken of certiﬁcate of analy-
sis, batch number, reception date, starting date of use, expiry date, con-
ditions and place of storage, and necessary validation.
The ESHRE Best Practice Guidelines (Thornhill et al., 2005) contain
PGD-speciﬁc recommendations concerning equipment and reagents;
although these are not formal requirements for accreditation, they
are of value to the laboratory and are expert guidelines which may
be considered by assessors. As such, it is recommended to incorpor-
ate them into the QMS.
Pre-examination procedures (ISO 15189: 5.4)
Validation of speciﬁc PGD protocols (PGD workup)
A peculiarity of many PGD protocols is that the clinical test used is
frequently developed for a speciﬁc couple. For example, the design
and use of speciﬁc probe combinations for patients carrying reciprocal
translocations and the use of informative markers for couples at risk of
transmitting a speciﬁc single-gene disorder. All such customized proto-
cols must be validated before clinical use. The report must deﬁne the
couple for whom the test has been validated, the exact protocol vali-
dated and how it was validated (number of single-cells analysed etc.).
This report should be authorized in the same way as any other report
(see ISO 15189 section 5.7). IQC should be in place for each validated
protocol so that just before the clinical PGD cycle, reagents and equip-
ment are checked to ensure that the IQC meets the standards set.
ISO 15189 sections 5.4–5.7 address the technical procedures that
have the greatest impact on patient safety. They are designed to assure
that the correct patient receives an accurate result for the correct test,
within an appropriate time. These sections of the standard are very
clear and precise and are easily applicable, even for laboratories
with little direct experience of quality management. Most laboratories
will already have thorough systems in place for the aspects addressed
by the standard; given the extreme importance, and the immediate
beneﬁt to patient care, it is recommended that laboratories focus
on the detailed requirements of the standard in this respect early in
the development of their QMS.
Documentation for this section must fulﬁl two groups of require-
ments: the ‘procedures for the PGD laboratory’ itself, and the
‘primary sample collection manual’ for users. PGD labs have speciﬁc
pre-analytical constraints compared with other genetics laboratories,
because such a large proportion of samples are irreplaceable and
require urgent testing. In a molecular or cytogenetics laboratory
samples will be mostly blood for DNA preparation or for leukocyte
culture. The PGD laboratory will often receive not only such conven-
tional samples (for conﬁrmation of familial anomalies), but also biopsied
cells (polar bodies, blastomeres or trophectoderm) and possibly whole
embryos or single embryonic cells (for conﬁrmation of the biopsy
result). When dealing with single-cell samples, there is very little
margin for error when collecting, receiving and processing a sample
for testing: poor handling of single cells for either PCR or FISH analysis
will probably lead to test failure, contamination or both.
The sample collection manual must include information for users (IVF
units, geneticists or others) and patients, test ordering and patient refer-
ral, specimen collection, handling and processing, transportation, recep-
tion, storage and eventual referral to other labs. Amore formal contract
between IVF centre and PGD lab, including the detailed Terms andCon-
ditions, may be appropriate. Clear and comprehensive information for
patients is important to assist informed consent and to help provide rea-
listic expectations regarding the likelihood of success. This is particularly
important for PGD, in which (i) diseases with different modes of inheri-
tance lead to different chances of success following PGD, (ii) the sensi-
tivity of the techniques used combined with the single-cell biopsy make
test failure more common than with routine diagnostic testing. The
exact content of written patient’s information materials will be speciﬁc
to the disease type and strategy used for diagnosis, but the practical
steps involved in PGD, test accuracy and reliability, misdiagnosis rate
and likely success rates are all essential items of information required
for patients, as stated previously in professional guidelines and rec-
ommendations (PGDIS, 2004; Thornhill et al., 2005) and, in some
cases, regulatory bodies (HFEA, 2009).
Specimen collection raises speciﬁc challenges for PGD since at
present, the biopsy and preparation of single blastomeres, polar
bodies or multiple cells from blastocyst biopsies is only conducted
by a relatively small number of practitioners worldwide. Furthermore,
the labelling and the number of cells to be removed at biopsy are criti-
cal. The laboratory should prepare very detailed SOPs describing
single cell preparation methods; it may also be appropriate to consider
offering training to the IVF clinics commissioning diagnostic tests.
The PGD laboratory should validate the sample transportation pro-
tocols from the commissioning IVF clinic to ensure that (i) specimens
are not lost or delayed, (ii) transport of cells does not compromise the
efﬁciency of PCR ampliﬁcation or FISH hybridization and (iii) any pre-
arranged turnaround times from sample preparation to result report-
ing can be met. Such validation is usually performed by a series of tests
involving: repeated transportation of non-critical materials,
dummy-runs and simulated cycles.
The standard insists on proper identiﬁcation of primary samples
(ISO 15189 section 5.4.5) and states unequivocally ‘Primary samples
lacking proper identiﬁcation shall not be accepted or processed by
the laboratory’. However, it also admits the possibility of accepting
critical samples (such as biopsied cells) that are inadequately labelled
under certain conditions. There is commonly pressure on the labora-
tory to accept samples despite insufﬁcient identiﬁcation; as it is critical
for the laboratory to avoid giving a result for the wrong sample, it is
recommended that a precise and comprehensive procedure be devel-
oped for the treatment of such situations, including the basic policy of
‘rejecting inadequately identiﬁed samples’. Rapid and frank communi-
cation with the referring clinician should be included in the procedure
to attempt to resolve the immediate problem and also to reduce the
risk of recurrence. The collection manual and/or request form should
also indicate clearly what the laboratory requires as identiﬁcation.
Once the samples arrive in the PGD laboratory, they should be
logged in as for any other clinical sample. The single-cell sensitivity
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and limited ability to re-test samples collected for PGD make it critical
to ensure that the correct test is ordered for the patient, after appro-
priate pre-test counselling and test development (if appropriate).
A written conﬁrmation of the speciﬁc test to be performed should
be received by the diagnostic laboratory, preferably in advance of
specimen receipt; this is best achieved using a requisition form pro-
vided by the diagnostic laboratory. Specimens arriving without such
documentation should, in principle, be rejected, with the same poten-
tial exceptions as described for unlabelled or incorrectly labelled
samples. The standard also requires that requests and samples be sys-
tematically ‘reviewed by authorized personnel’ (ISO 15189 section
5.4.10); this must be documented, for example, by initials and date
on the request form. Non-conformities at reception should be
treated in a timely manner, proportionate to the degree of urgency;
particularly in the PGD lab. This may require speciﬁc training for the
personnel involved to ensure they are sensitive to sample storage
requirements, additives and urgency.
Examination (test) procedures (ISO 15189:
5.5)
There should be a written procedure for the conduct of all examin-
ations and moreover that the adherence to examination procedures
is essential to ensure a consistent and reliable quality service. For
the ‘examination procedure’, this includes the selection and validation
of the examination procedure, and assuring the quality of the
examination.
Only validated protocols should be used for clinical PGD (see ISO
15189 section 5.4). Critical steps in the diagnosis will need to be
appropriately witnessed. Since some tests are individual protocols
for speciﬁc couples, it may be useful to prepare a protocol
summary table where the person performing the diagnosis and the
witness can record exactly what they did for each critical stage of
the protocol (and both sign that they did it/witnessed it), e.g. for a
FISH case, the identity and volume of probes used and the denatura-
tion and hybridization times. Competence records should be kept
indicating which personnel are authorized to perform particular
procedures.
The laboratory director shall be responsible for ensuring that the
content of examination procedures are complete, current and have
been thoroughly reviewed. The same requirements for document
control should also apply to electronic manuals.
There needs to be a policy on the control of ‘process and quality
records’. In this document, there is information on the types of labora-
tory forms (and their reference numbers), how these forms are stored
and where they are stored for easy retrieval. Individual staff should not
store this information in personal laboratory books. This information
must be readily available and accessible to those with documented
access. It is also important to know what documentation needs to
come with samples from IVF laboratories (PGD referral forms).
Ideally, basic information should be obtained from the IVF unit regard-
ing the IVF cycle, such as the number of eggs collected, number ferti-
lized, method of biopsy etc. In some cases (e.g. full members of the
ESHRE PGD Consortium), this is essential. Such information may be
considered as good practice, especially for those centres operating
transport PGD. The policy should also contain information on how
the results of the PGD workups and cycle results are stored (such
as gels, FISH images etc.). This MP also needs to contain information
on patient consent but this would normally come under the control of
the IVF unit. Lastly, the document needs to contain information on
where the quality records are stored (audit reports, EQA results,
annual management reviews and user satisfaction reports).
Assuring quality of examination procedures
(ISO 15189: 5.6)
Validation and IQC of the protocol before the clinical case (see ISO
15189 section 5.4), and monitoring of the quality indicators for
cases (see ISO 15189 section 4.12), will ensure that the quality of
examination procedures is continuously monitored.
External quality assessment
A policy on EQA needs to include details of the EQA that the PGD lab-
oratory uses, who in the PGD centre is responsible for doing the EQA
(processing the samples etc.) and how the EQA is reported. An accred-
itation system cannot operate unless there is an EQA or equivalent
which can monitor performance. The PGD Consortium has set up
schemes for EQA of FISH in collaboration with CEQA (Cytogenetics
European Quality Assessment, www.ceqa-cyto.eu) and PCR in collab-
oration with UK NEQAS (UK National External Quality Assessment
Scheme, http://www.ukneqas.org.uk).
Laboratories should also consider participation in genetics EQA
schemes which are not PGD-speciﬁc, especially when parental and/
or familial testing is performed. When no EQA scheme is available
for a particular disease or type of analysis, the laboratory should con-
sider sample exchange with another laboratory to demonstrate the
accuracy of testing.
Post-examination procedures and reporting
of results (ISO 15189: 5.7)
The post-examination procedure could be deﬁned as ‘processes fol-
lowing the examination, including systematic review, formatting and
Table VII Items that should be included in the PGD
cycle report which is sent to the IVF unit.
Name (and address) of the PGD unit
Name (and address) of the IVF unit
Name and number of the report form (as used for document control)
Date of the egg collection
Date of the report
Unique patient number
Unique cycle identifying number
A summary of the results—ideally in tabulated form
Interpretative comments—which embryos should be considered for
transfer
(Highlighting of abnormal results)
Identiﬁcation of the person performing the diagnosis and the witness
Identiﬁcation of the person verifying the results and authorizing the release
of the report and their signature
Pagination to include the actual and total number of pages
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interpretation, authorization for release, reporting and transmission of
result and storage of the samples of the examinations’ CPA (2007).
The policy for the post-examination phase needs to include details
of who reports the results and on what forms, the conﬁdentiality of
the reports, the internal (detailed laboratory report of the PGD
case) and the external report (the summary report for the IVF unit),
how the reports are authorized and by whom and how the results
are reported. Results shall be legible, without mistakes and reported
to persons authorized to receive and use this kind of medical
information.
The laboratory shall have clearly documented procedures for
releasing of examination results, including designated personnel
responsible for releasing the results and to whom they can be
released. It is recommended not to release the information on the
embryos to be transferred verbally (by phone) to prevent a
misunderstanding which could result in the transfer of the wrong
embryo. Therefore only emailed, faxed or hardcopy reports should
be used in PGD. Only the latter two can contain an authorizing signa-
ture unless using an approved electronic signature in scanned reports
by email. For PGD, it may be useful to email a provisional report so
that the embryologists can score the embryos to determine their
development since the biopsy. This will be useful information when
discussing the results with the patients (if customary) and deciding
which embryos to replace. However, a hardcopy report signed by
the authorizing personnel is needed by the IVF unit before embryo
transfer is conducted. If this is faxed, provisions need to be in place
to ensure that it is faxed to the correct location (receipt conﬁrmation)
and that the fax machine is secure (i.e. in a controlled location). It is a
good practice for the PGD team to be available to discuss the report
with the IVF team.
Table VIII Report form 1-PGD INTERNAL REPORT.
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The following items should be part of the PGD report (Table VII)
and examples of report forms for PGD are shown in Tables VIII
and IX.
Conclusion
Regulations or recommendations in many countries are already requir-
ing that any diagnostic laboratory should be accredited (OECD, 2007;
HFEA, 2009) and the ESHRE PGD Consortium recommends that all
PGD centres should be preparing for accreditation (Goossens et al.,
2009). The implementation of a comprehensive QMS and the prep-
aration for accreditation is initially a daunting experience, and in this
document, we have addressed speciﬁc issues relating to PGD, to
make this process easier and to provide a degree of harmonization
between laboratories. Accreditation is a time-consuming process
both in the initial and in the maintenance phases. However, the value
of a comprehensive QMS rapidly becomes clear to any PGD centre,
along with the realization that many areas were potentially vulnerable.
A good starting point is to involve the whole PGD team in the QMS,
especially in writing SOPs for the different laboratory procedures and
to put in place appropriate instructions and documentation for labora-
tory instruments. This can be followed by ensuring all the personnel
information is in place (including the training manual), after which the
quality manual and the detailed policies can follow.
PGD is a multidisciplinary procedure that requires excellent organ-
ization and communication. To date, there are no nationally or
Table IX Report form 2-Report to be sent to the IVF unit.
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internationally recognized training programmes for PGD (as exist in
other ﬁelds of diagnosis, such as cytogenetics and molecular genetics).
For this reason, development of a well-deﬁned internal training pro-
gramme, maintenance of log books and CPD for all personnel involved
in PGD is essential. Maintaining a quality system is an active process
that requires everyone on board, requiring continuous education
and motivation of all personnel. A well-maintained QMS will standar-
dize the PGD service, prevent reliance on individuals and generate a
more reliable service ultimately leading to improved patient care as
measured by increased effectiveness for both the IVF and PGD
centres involved (Vendrell et al., 2009).
The ESHRE PGD Consortium has organized two workshops to
address the issues relating to accrediting a PGD centre (www.eshre.
com). In addition, four new guidelines on PGD are in preparation.
They will be on: organization of the PGD centre, FISH, PCR and
embryo biopsy/embryology (Harton et al., in preparation). This
paper should be read in conjunction with the new guidelines for
anyone working in the ﬁeld of PGD.
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